Artelo Biosciences raises $9.5M, adopts Solana as treasury asset

Published 04/08/2025, 12:34

Artelo Biosciences Inc. (NASDAQ:ARTL) completed a $9.475 million private placement and announced plans to adopt Solana’s SOL cryptocurrency as a reserve asset, making it the first publicly traded pharmaceutical company to take this approach.

The clinical-stage pharmaceutical company entered into a securities purchase agreement priced at $10.45 per share, consisting of 906,687 shares of common stock and accompanying warrants. The transaction includes three-year warrants to purchase additional shares at exercise prices of $10.20 and $50.00 per share.

Bartosz Lipiński, former head of engineering at Solana Labs and inventor of Metaplex, serves as the lead investor and will act as a technical advisor through his company CUBE. CUBE will handle secure storage, staking, and DeFi execution for Artelo’s digital asset treasury.

"By adopting SOL as a treasury asset, Artelo is positioning itself for sustainable growth and resilience, leveraging a cutting-edge monetary network to enhance shareholder value," said Lipiński, who is co-founder and CEO of Cube Group.

Artelo’s board approved authorization to expand the company’s SOL treasury strategy through staged investments over time while maintaining adequate working capital for therapeutic development. The company develops treatments for cancer, pain, dermatological and neurological conditions by modulating lipid-signaling pathways.

Chief Executive Officer Gregory Gorgas stated the initiative reflects the company’s commitment to innovative capital management and aims to enhance long-term shareholder value through exposure to digital assets.

The private placement is expected to close around August 5, 2025, subject to customary closing conditions. R.F. Lafferty & Co. served as advisor for the transaction. This brings Artelo’s aggregate proceeds from at-the-market private placements since June 2025 to $10.9 million.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.